Form 8-K12G3 - Notification of securities of successor issuers deemed to registered [Section 12]:
SEC Accession No. 0001493152-24-042727
Filing Date
2024-10-28
Accepted
2024-10-28 17:23:47
Documents
7
Period of Report
2024-10-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k12g3.htm 8-K12G3 70195
2 ex2-1.htm EX-2.1 55163
3 ex3-1.htm EX-3.1 223793
4 ex3-2.htm EX-3.2 94051
5 ex10-1.htm EX-10.1 26622
6 ex10-2.htm EX-10.2 197327
7 ex14-1.htm EX-14.1 151262
  Complete submission text file 0001493152-24-042727.txt   819942
Mailing Address 960 SOUTH BROADWAY, SUITE 118 HICKSVILLE NY 11081
Business Address 960 SOUTH BROADWAY, SUITE 118 HICKSVILLE NY 11081 516-595-9544
Nascent Pharma Holdings, Inc. (Filer) CIK: 0002042814 (see all company filings)

EIN.: 331600116 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 8-K12G3 | Act: 34 | File No.: 000-56703 | Film No.: 241401948